Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol
European Heart Journal Open · 29.12.2023 · 4 (1)
DOI: 10.1093/ehjopen/oeae001 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 08.01.2024. Verfasst von Andreas Leiherer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, A-6800 Feldkirch, Austria. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vorarlberger Landesregierung.
Abstract (Originalsprache)
Aims
Low-density lipoprotein cholesterol (LDL-C) is the best documented cardiovascular risk predictor and at the same time serves as a target for lipid-lowering therapy. However, the power of LDL-C to predict risk is biased by advanced age, comorbidities, and medical treatment, all known to impact cholesterol levels. Consequently, such biased patient cohorts often feature a U-shaped or inverse association between LDL-C and cardiovascular or overall mortality. It is not clear whether these constraints for risk prediction may likewise apply to other lipid risk markers in particular to ceramides and phosphatidylcholines. Methods and results In this observational cohort study, we recorded cardiovascular mortality in 1195 patients over a period of up to 16 years, comprising a total of 12 262 patient-years. The median age of patients at baseline was 67 years. All participants were either consecutively referred to elective coronary angiography or diagnosed with peripheral artery disease, indicating a high cardiovascular risk. At baseline, 51% of the patients were under statin therapy. We found a U-shaped association between LDL-C and cardiovascular mortality with a trough level of around 150 mg/dL of LDL-C. Cox regression analyses revealed that LDL-C and other cholesterol species failed to predict cardiovascular risk. In contrast, no U-shaped but linear association was found for ceramide- and phosphatidylcholine-containing markers and these markers were able to significantly predict the cardiovascular risk even after multivariate adjustment.
Conclusion
We thus suggest that ceramides- and phosphatidylcholine-based predictors rather than LDL-C may be used for a more accurate cardiovascular risk prediction in high-risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, A-6800 Feldkirch, Austria.
- Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein.
- Medical Central Laboratories, Carinagasse 41, A-6800 Feldkirch, Austria.
- Department of Internal Medicine III, Academic Teaching Hospital Feldkirch, Carinagasse 47, A-6800 Feldkirch, Austria.
- Finnish Cardiovascular Research Center, University of Tampere, FI-33014 Tampere, Finland.
- Zora Biosciences, FI-02150 Espoo, Finland.
ORCID-Profile: Andreas Leiherer, Axel Muendlein, Heinz Drexel
Förderung
- Vorarlberger Landesregierung
Zitieren
APA
Leiherer, A., Muendlein, A., Saely, C. H., Laaksonen, R., Fraunberger, P., & Drexel, H. (2023). Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol. European Heart Journal Open, 4(1). https://doi.org/10.1093/ehjopen/oeae001
Vancouver
Leiherer A, Muendlein A, Saely CH, Laaksonen R, Fraunberger P, Drexel H. Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol. European Heart Journal Open. 2023;4(1). doi:10.1093/ehjopen/oeae001
BibTeX
@article{Leiherer2023,
author = {Leiherer, Andreas and Muendlein, Axel and Saely, Christoph H and Laaksonen, Reijo and Fraunberger, Peter and Drexel, Heinz},
title = {Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol},
journal = {European Heart Journal Open},
year = {2023},
volume = {4},
number = {1},
doi = {10.1093/ehjopen/oeae001}
}
EUVIMED